Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
15
NCT06024265
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
Phase: Early Phase 1
Role: Lead Sponsor
Start: Apr 4, 2023
Completion: Dec 31, 2024